SARS MERS, Sf9 Active
Sf9, Baculovirus cells.
Middle East respiratory syndrome coronavirus, Human betacoronavirus 2c EMC/2012, MERS-CoV, MERS, MERSCoV SP, Spike glycoprotein, S glycoprotein, S, Spike protein, E2, Peplomer protein
Greater than 85.0% as determined by SDS-PAGE.
Description
SARS MERS Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 1285 amino acids (18-1296 aa) and having a molecular mass of 141.6kDa. SARS MERS is fused to a 6 amino acid His-tag at C-terminus & purified by proprietary chromatographic techniques.
Product Specs
Middle East respiratory syndrome coronavirus, Human betacoronavirus 2c EMC/2012, MERS-CoV, MERS, MERSCoV SP, Spike glycoprotein, S glycoprotein, S, Spike protein, E2, Peplomer protein
Sf9, Baculovirus cells.
YVDVGPDSVK SACIEVDIQQ TFFDKTWPRP IDVSKADGII YPQGRTYSNI TITYQGLFPY QGDHGDMYVY SAGHATGTTP QKLFVANYSQ DVKQFANGFV VRIGAAANST GTVIISPSTS ATIRKIYPAF MLGSSVGNFS DGKMGRFFNH TLVLLPDGCG TLLRAFYCIL EPRSGNHCPA GNSYTSFATY HTPATDCSDG NYNRNASLNS FKEYFNLRNC TFMYTYNITE DEILEWFGIT QTAQGVHLFS SRYVDLYGGN MFQFATLPVY DTIKYYSIIP HSIRSIQSDR KAWAAFYVYK LQPLTFLLDF SVDGYIRRAI DCGFNDLSQL HCSYESFDVE SGVYSVSSFE AKPSGSVVEQ AEGVECDFSP LLSGTPPQVY NFKRLVFTNC NYNLTKLLSL FSVNDFTCSQ ISPAAIASNC YSSLILDYFS YPLSMKSDLS VSSAGPISQF NYKQSFSNPT CLILATVPHN LTTITKPLKY SYINKCSRLL SDDRTEVPQL VNANQYSPCV SIVPSTVWED GDYYRKQLSP LEGGGWLVAS GSTVAMTEQL QMGFGITVQY GTDTNSVCPK LEFANDTKIA SQLGNCVEYS LYGVSGRGVF QNCTAVGVRQ QRFVYDAYQN LVGYYSDDGN YYCLRACVSV PVSVIYDKET KTHATLFGSV ACEHISSTMS QYSRSTRSML KRRDSTYGPL QTPVGCVLGL VNSSLFVEDC KLPLGQSLCA LPDTPSTLTP RSVRSVPGEM RLASIAFNHP IQVDQLNSSY FKLSIPTNFS FGVTQEYIQT TIQKVTVDCK QYVCNGFQKC EQLLREYGQF CSKINQALHG ANLRQDDSVR NLFASVKSSQ SSPIIPGFGG DFNLTLLEPV SISTGSRSAR SAIEDLLFDK VTIADPGYMQ GYDDCMQQGP ASARDLICAQ YVAGYKVLPP LMDVNMEAAY TSSLLGSIAG VGWTAGLSSF AAIPFAQSIF YRLNGVGITQ QVLSENQKLI ANKFNQALGA MQTGFTTTNE AFQKVQDAVN NNAQALSKLA SELSNTFGAI SASIGDIIQR LDVLEQDAQI DRLINGRLTT LNAFVAQQLV RSESAALSAQ LAKDKVNECV KAQSKRSGFC GQGTHIVSFV VNAPNGLYFM HVGYYPSNHI EVVSAYGLCD AANPTNCIAP VNGYFIKTNN TRIVDEWSYT GSSFYAPEPI TSLNTKYVAP QVTYQNISTN LPPPLLGNST GIDFQDELDE FFKNVSTSIP NFGSLTQINT TLLDLTYEML SLQQVVKALN ESYIDLKELG NYTYYNKWPH HHHHH.
Product Science Overview
The SARS MERS Spike Recombinant, Sf9 Active, is a recombinant protein derived from the spike proteins of the SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) and MERS-CoV (Middle East Respiratory Syndrome Coronavirus). This recombinant protein is produced using the Sf9 insect cell line, which is a widely used system for the expression of recombinant proteins.
The production of the SARS MERS Spike Recombinant involves several key steps:
- Gene Cloning: The genes encoding the spike proteins of SARS-CoV and MERS-CoV are cloned into a suitable expression vector.
- Transfection: The recombinant vector is then introduced into Sf9 cells, a cell line derived from the fall armyworm (Spodoptera frugiperda).
- Protein Expression: The Sf9 cells are cultured under conditions that promote the expression of the recombinant spike proteins.
- Purification: The expressed proteins are harvested and purified using various chromatographic techniques to ensure high purity and activity.
The SARS MERS Spike Recombinant, Sf9 Active, has several important applications in research and vaccine development:
- Vaccine Development: The recombinant spike proteins are used as antigens in the development of vaccines against SARS-CoV and MERS-CoV. These proteins can elicit an immune response in the host, providing protection against the viruses.
- Diagnostic Tools: The recombinant proteins are also used in the development of diagnostic assays to detect antibodies against SARS-CoV and MERS-CoV in patient samples.
- Research: Researchers use the recombinant spike proteins to study the structure and function of the spike proteins, as well as their interactions with host cell receptors.
Studies have shown that vaccines developed using the SARS MERS Spike Recombinant, Sf9 Active, are safe and immunogenic. Clinical trials have demonstrated that these vaccines can induce strong immune responses, including the production of neutralizing antibodies and T-cell responses . The use of the Sf9 cell line for protein expression is advantageous due to its high yield and scalability, making it suitable for large-scale production .
